{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:15:10Z","timestamp":1779110110352,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hashimoto encephalopathy has multiple clinical presentations, and other than the presence of thyroid antibody, laboratory and imaging investigations are all non-specific. Data specific to the clinical presentations and treatment outcomes of patients with Hashimoto encephalopathy in Thailand remain scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To retrospectively investigate the clinical presentations and treatment outcomes of patients with Hashimoto encephalopathy at Siriraj Hospital.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients who presented with acute encephalopathy at our center during July 2012-March 2017 were evaluated for eligibility. The inclusion criteria were positive anti-thyroperoxidase (anti-TPO) or anti-thyroglobulin (anti-Tg) in serum with negative neuronal antibody in serum or cerebral spinal fluid (CSF). Clinical presentations, symptom duration, laboratory results of thyroid status and thyroid autoantibody, CSF study, and clinical outcomes were collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 204 patients who presented with encephalopathy, 31 (15.2%) were positive for the anti-TPO or anti-Tg antibody. Of those, 13 patients met the diagnostic criteria for Hashimoto encephalopathy. Clinical presentations included cognitive impairment (76.9%), clouding of consciousness (46.2%), and behavior change (30.8%). The neuropsychiatric presentations were visual hallucination (30.8%), auditory hallucination (15.4%), delusion (7.7%), and mood disturbance (23.1%). Other clinical presentations included seizure (38.5%), abnormal movement (23.1%), sleep disturbance (38.5%), ataxia (46.2%), stroke-like episode (15.4%), and fever (15.4%). Most patients (76.9%) had onset within &lt;\u20093 months. Regarding outcomes, 1 patient who did not receive corticosteroid died from status epilepticus and septic shock. Among the 12 patients who received corticosteroid, 9 (75%) had marked improvement, 1 (8.3%) had slight improvement, and 2 (16.6%) had no clinical improvement. Seven patients (53.9%) had normal thyroid function, 4 patients (30.8%) had subclinical hypothyroidism, and 2 patients (15.4%) had subclinical hyperthyroidism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results of this study revealed cognitive impairment, neuropsychiatric symptoms, seizure, ataxia, and sleep disturbance to be common manifestations of Hashimoto encephalopathy. This condition should always be considered in individuals with subacute onset of unexplained cognitive impairment or cerebellar ataxia. Laboratory and neuroimaging investigations were all found to be nonspecific in Hashimoto encephalopathy. Most patients responded well to treatment, so clinical suspicion and early diagnosis and treatment will lead to improved patient outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03305-4","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T10:02:30Z","timestamp":1695376950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical presentations and treatment outcomes of Hashimoto encephalopathy at Siriraj Hospital \u2013 Thailand\u2019s largest national tertiary referral center"],"prefix":"10.1186","volume":"23","author":[{"given":"Chaisak","family":"Dumrikarnlert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smathorn","family":"Thakolwiboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vorapun","family":"Senanarong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"3305_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/archneur.63.2.197","volume":"63","author":"P Castillo","year":"2006","unstructured":"Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch neurol. 2006;63:197\u2013202.","journal-title":"Arch neurol"},{"key":"3305_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/BF00900946","volume":"243","author":"I Kothbauer-Margreiter","year":"1996","unstructured":"Kothbauer-Margreiter I, Sturzenegger M, Komor J, et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996;243:585\u201393.","journal-title":"J Neurol"},{"key":"3305_CR3","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1212\/WNL.0b013e3182582fd4","volume":"78","author":"M Afshari","year":"2012","unstructured":"Afshari M, Afshari ZS, Schuele SU. Pearls & oy-sters: Hashimoto encephalopathy. Neurology. 2012;78:e134\u20137.","journal-title":"Neurology"},{"key":"3305_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000342217","volume":"69","author":"A Matsunaga","year":"2013","unstructured":"Matsunaga A, Ikawa M, FujiiA, et al. Hashimoto\u2019s encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Eur Neurol. 2013;69:14\u201320.","journal-title":"Eur Neurol"},{"key":"3305_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1444.018","volume":"1142","author":"N Schiess","year":"2008","unstructured":"Schiess N, Pardo CA. Hashimoto\u2019s encephalopathy. Ann NY Acad Sci. 2008;1142:254\u201365.","journal-title":"Ann NY Acad Sci"},{"key":"3305_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11910-014-0476-2","volume":"14","author":"HS Kirshner","year":"2014","unstructured":"Kirshner HS. Hashimoto\u2019s Encephalopathy: a brief review. Curr Neurol Neurosci Rep. 2014;14:476.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"3305_CR7","doi-asserted-by":"crossref","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Ejma M. Hashimoto Encephalopathy-Still more questions than answers. Cells 2022 Sep 14;11(18):2873.","DOI":"10.3390\/cells11182873"},{"key":"3305_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11910-023-01255-5","volume":"23","author":"J Chaudhuri","year":"2023","unstructured":"Chaudhuri J, Mukherjee A, Chakravarty A. Hashimoto\u2019s Encephalopathy: Case Series and Literature Review. Curr Neurol Neurosci Rep. 2023;23:167\u201375.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"3305_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.autrev.2016.09.008","volume":"15","author":"C Laurent","year":"2016","unstructured":"Laurent C, Capron J, Quillerou B, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): characteristics, treatment and outcome in 251 cases from the literature. Autoimmun Rev. 2016;15:1129\u201333.","journal-title":"Autoimmun Rev"},{"key":"3305_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1176\/jnp.18.1.14","volume":"18","author":"GA Marshall","year":"2006","unstructured":"Marshall GA, Doyle JJ. Long-term treatment of Hashimoto\u2019s encephalopathy. J Neuropsychiatry Clin Neurosci. 2006;18:14\u201320.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3305_CR11","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2174\/0929867033456873","volume":"10","author":"A Chaudhuri","year":"2003","unstructured":"Chaudhuri A, Behan PO. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto\u2019s encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem. 2003;10:1945\u201353.","journal-title":"Curr Med Chem"},{"issue":"7872","key":"3305_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","volume":"2","author":"G Teasdale","year":"1974","unstructured":"Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2(7872):81\u20134.","journal-title":"Lancet"},{"issue":"5","key":"3305_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1532-5415.2008.01674.x","volume":"56","author":"LA Wei","year":"2008","unstructured":"Wei LA, Fearing MA, Sternberg EJ, et al. The confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc. 2008;56(5):823.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"3305_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391\u2013404.","journal-title":"Lancet Neurol"},{"issue":"2","key":"3305_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/archneur.60.2.164","volume":"60","author":"JY Chong","year":"2003","unstructured":"Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003;60(2):164\u201371.","journal-title":"Arch Neurol"},{"key":"3305_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000008785","volume":"94","author":"S Mattozzi","year":"2020","unstructured":"Mattozzi S, Sabater L, Escudero D, et al. Hashimoto encephalopathy in the 21st century. Neurology. 2020;94:e1\u2013e8.","journal-title":"Neurology"},{"issue":"12","key":"3305_CR17","first-page":"e11857","volume":"12","author":"A Sliwinska","year":"2020","unstructured":"Sliwinska A, Fumuso P, Stringer B, et al. Hashimoto Encephalopathy With Status Epilepticus Cureus. 2020;12(12):e11857.","journal-title":"Hashimoto Encephalopathy With Status Epilepticus Cureus"},{"issue":"1","key":"3305_CR18","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1212\/WNL.0000000000012191","volume":"97","author":"M Guasp","year":"2021","unstructured":"Guasp M, Gin\u00e9-Serv\u00e9n E, Maudes E, et al. Clinical, neuroimmunologic, and CSF investigations in First Episode Psychosis. Neurology. 2021;97(1):e61\u2013e75.","journal-title":"Neurology"},{"issue":"9","key":"3305_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaneurol.2013.3216","volume":"70","author":"MS Kayser","year":"2013","unstructured":"Kayser MS, Titulaer MJ, Gresa-Arribas N, et al. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133\u20139.","journal-title":"JAMA Neurol"},{"issue":"24","key":"3305_CR20","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1212\/WNL.0000000000001682","volume":"84","author":"R H\u00f6ftberger","year":"2015","unstructured":"H\u00f6ftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 2015;84(24):2403\u201312.","journal-title":"Neurology"},{"issue":"11","key":"3305_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1212\/WNL.0000000000002476","volume":"86","author":"AS Lopez-Chiriboga","year":"2016","unstructured":"Lopez-Chiriboga AS, Komorowski L, K\u00fcmpfel T, et al. Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology. 2016;86(11):1009\u201313.","journal-title":"Neurology"},{"issue":"2pt1","key":"3305_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/WNL.41.2_Part_1.228","volume":"41","author":"PJ Shaw","year":"1991","unstructured":"Shaw PJ, Walls TJ, Newman PK, et al. Hashimoto\u2019s encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers\u2014report of 5 cases. Neurology. 1991;41(2pt1):228\u201333.","journal-title":"Neurology"},{"key":"3305_CR23","doi-asserted-by":"crossref","unstructured":"Alazzeh A, Jaroudi S, Gooch M et al. Focal neurological presentation in Hashimoto\u2019s encephalopathy mimicking a vascular occlusion of the middle cerebral artery.BMJ Case Rep 2017; 2017:bcr-2017-219933.","DOI":"10.1136\/bcr-2017-219933"},{"key":"3305_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pediatrneurol.2016.02.003","volume":"59","author":"BR Graham","year":"2016","unstructured":"Graham BR, Shiff N, Nour M, et al. Hashimoto Encephalopathy presenting with Stroke-Like episodes in an adolescent female: a case report and literature review. Pediatr Neurol. 2016;59:62\u201370.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"3305_CR25","doi-asserted-by":"publisher","first-page":"fcaa233","DOI":"10.1093\/braincomms\/fcaa233","volume":"3","author":"C Valencia-Sanchez","year":"2021","unstructured":"Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al. Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun. 2021;3(2):fcaa233.","journal-title":"Brain Commun"},{"issue":"8","key":"3305_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00415-006-0170-7","volume":"253","author":"F Ferracci","year":"2006","unstructured":"Ferracci F, Carnevale A. The neurological disorder associated with thyroid autoimmunity. J Neurol. 2006;253(8):975\u201384.","journal-title":"J Neurol"},{"issue":"9","key":"3305_CR27","first-page":"16817","volume":"8","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Yang H, Xiao F. Hashimoto\u2019s encephalopathy: a report of three cases and relevant literature reviews. Int J Clin Exp Med. 2015;8(9):16817\u201326.","journal-title":"Int J Clin Exp Med"},{"key":"3305_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3174\/ajnr.A5086","volume":"38","author":"BP Kelley","year":"2017","unstructured":"Kelley BP, Patel SC, Marin HL, et al. Autoimmune encephalitis: pathophysiology and imaging review of an overlooked diagnosis. AJNR Am J Neuroradiol. 2017;38:1070\u20138.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"3305_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00023210-200721100-00002","volume":"21","author":"R Mocellin","year":"2007","unstructured":"Mocellin R, Walterfang M, Velakoulis D, et al. Hashimoto\u2019s encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007;21(10):799\u2013811.","journal-title":"CNS Drugs"},{"issue":"6","key":"3305_CR30","first-page":"e15697","volume":"13","author":"V Jegatheeswaran","year":"2021","unstructured":"Jegatheeswaran V, Chan M, Chen YA. MRI findings of two patients with Hashimoto Encephalopathy. Cureus. 2021;13(6):e15697.","journal-title":"Cureus"},{"key":"3305_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0014-5793(02)03307-0","volume":"528","author":"H Ochi","year":"2002","unstructured":"Ochi H, Horiuchi I, Araki N, et al. Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto encephalopathy. FEBS Lett. 2002;528:197\u2013202.","journal-title":"FEBS Lett"},{"key":"3305_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jneuroim.2005.02.004","volume":"162","author":"A Fujii","year":"2005","unstructured":"Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of \u03b1-enolase are a useful diagnostic marker of Hashimoto encephalopathy. J Neuroimmunol. 2005;162:130\u20136.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"3305_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jneuroim.2007.01.018","volume":"185","author":"M Yoneda","year":"2007","unstructured":"Yoneda M, Fujii A, Ito A, et al. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto encephalopathy. J Neuroimmunol. 2007;185(1\u20132):195\u2013200.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"3305_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.autrev.2006.10.004","volume":"6","author":"B Terrier","year":"2007","unstructured":"Terrier B, Degand N, Guilpain P, et al. Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev. 2007;6(3):176\u201382.","journal-title":"Autoimmun Rev"},{"key":"3305_CR35","doi-asserted-by":"publisher","first-page":"673339","DOI":"10.3389\/fneur.2021.673339","volume":"12","author":"E Sechi","year":"2021","unstructured":"Sechi E, Flanagan EP. Antibody-mediated Autoimmune Diseases of the CNS: Challenges and Approaches to diagnosis and management. Front Neurol. 2021;12:673339.","journal-title":"Front Neurol"},{"issue":"S1","key":"3305_CR36","first-page":"25","volume":"17","author":"S Dupont","year":"2019","unstructured":"Dupont S. Non convulsive status epilepticus in the elderly. Geriatr Psychol Neuropsychiatr Vieil. 2019;17(S1):25\u201330.","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"issue":"1","key":"3305_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaneurol.2022.4251","volume":"80","author":"EP Flanagan","year":"2023","unstructured":"Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30\u20139.","journal-title":"JAMA Neurol"},{"issue":"2","key":"3305_CR38","doi-asserted-by":"publisher","first-page":"fcaa233","DOI":"10.1093\/braincomms\/fcaa233","volume":"3","author":"C Valencia-Sanchez","year":"2021","unstructured":"Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al. Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun. 2021;3(2):fcaa233.","journal-title":"Brain Commun"},{"key":"3305_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/ane.12556","volume":"134","author":"S Litmeier","year":"2016","unstructured":"Litmeier S, Pruss H, Witsch E, et al. Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT. Acta Neurol Scand. 2016;134:452\u20137.","journal-title":"Acta Neurol Scand"},{"key":"3305_CR40","doi-asserted-by":"crossref","unstructured":"Riangwiwat T, Sangtian J, Sriphrapradang C. Steroid-responsive encephalopathy: an under recognized aspect of Hashimoto\u2019s thyroiditis. Case Reports 2015; 2015: bcr2014208969.","DOI":"10.1136\/bcr-2014-208969"},{"key":"3305_CR41","doi-asserted-by":"crossref","unstructured":"Termsarasab P, Pitakpatapee Y, Frucht SJ et al. Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) presenting with pure cerebellar Ataxia. Tremor Other Hyperkinet Mov (N Y) 2018; 8: 585.","DOI":"10.5334\/tohm.420"},{"key":"3305_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.35755\/jmedassocthai.2021.06.12371","volume":"104","author":"A Charoensri","year":"2021","unstructured":"Charoensri A, Tunlayadechanont S, Apiwattanakul M, et al. Autoimmune antibody in encephalopathic patients: a pilot study. J Med Assoc Thai. 2021;104:943\u201350.","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"3305_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4103\/0976-3147.158753","volume":"6","author":"PM Sharma","year":"2015","unstructured":"Sharma PM, Javali M, Mahale R, et al. Hashimoto encephalopathy: a study of the clinical profile, radiological and electrophysiological correlation in a Tertiary Care Center in South India. J Neurosci Rural Pract. 2015;6(3):309\u201314.","journal-title":"J Neurosci Rural Pract"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03305-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T21:46:55Z","timestamp":1700257615000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03305-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03305-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"24 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for this study was approved by the Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (COA no. 534\/2016). Written informed consent was not obtained from study participants due to our study\u2019s retrospective, anonymity-preserving design. The ethics committee that waivered the need for informed consent was also Siriraj Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. All authors confirm that the research was conducted in accordance with the Declaration of Helsinki. Ethical approval was granted in 2016 and data collection was start in 2017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no personal or professional conflicts of interest relating to any aspect of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"334"}}